Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06464107 · ClinicalTrials.gov registry record · NA
Endometrial Cell Collection With the PadKit
A NA study of Neoplasms, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06464107 is a NA study of Neoplasms that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 80 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06464107, a NA study of Neoplasms, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.
Conditions Studied
Interventions
- DEVICE PadKit™ from Preprogen
Study Locations (2)
New Jersey
- Jersey Shore University Medical Center - Neptune City
- Riverview Medical Center - Red Bank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-05-31 |
| Est. Completion | 2026-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06464107
The ClinicalTrials.gov registry entry for NCT06464107 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PadKit™ from Preprogen is the first listed.
NCT06464107 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06464107 about?
NCT06464107 is a clinical study titled "Endometrial Cell Collection With the PadKit". All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial ce...
What is the current status of trial NCT06464107?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-05-31. Estimated completion is 2026-05-30.
What conditions does trial NCT06464107 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06464107?
The interventions under investigation include: PadKit™ from Preprogen (DEVICE).
Who is sponsoring clinical trial NCT06464107?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06464107 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
RECRUITING · NA
-
Screening Strategies Among High-risk Populations for Anal Cancer
RECRUITING · NA
-
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.